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Abstract
Background: Buspirone is a partial 5-HT1A receptor agonist. Animal studies have shown that
modulation of serotoninergic transmission at the 5-HT1A receptor can induce analgesia in acute
pain models. However, no studies have been published so far on the effects of serotonin receptor
agonists on pain perception in humans.
Methods: The effects of buspirone (30 mg p.o.) on thermal sensory and pain thresholds were
investigated in twelve female volunteers (26 ± 2 yrs) in a prospective, randomized, double-blind,
double-dummy, placebo-controlled study with morphine (10 mg i.v.) as positive control.
Results: Morphine significantly increased the heat pain detection threshold (ΔT: placebo 1.0°C and
1.3°C, p < 0.05) at 60 minutes. Buspirone caused mild sedation in six participants at 60 minutes,
but was without effect on any of the measured parameters.
Conclusion: Buspirone in the maximal recommended dose was without significant effect on
thermal pain. However, as it is only a partial agonist at the 5-HT1A receptor and also acts on other
receptor types, the negative results of the present study do not rule out a possible analgesic effect
of more specific 5-HT1A receptor agonists.
Background
Numerous animal studies have implicated serotonergic
pathways, particularly the 5-HT1a receptors, in pain per-
ception [1,2]. Serotonin-transporter deficient mice which
have lower levels of tissue serotonin have reduced inflam-
matory pain and thermal hyperalgesia [3]. 5-HT1a defi-
cient (knock-out) mice exhibit higher thermal
hypersensitivity than naive, non-knock-out mice [4]. The
5-HT1a agonist 8-OH-DPAT has analgesic properties in the
hot-plate and tail-flick test in mice [5]. Various other 5-
HT1a agonists, including the partial agonist buspirone,
also exhibit analgesic effects in the hot-plate test in mice
[6] and in a rat model of surgical pain [7]. Accordingly, 5-
HT1a  receptor antagonists block analgesia induced by
stimulation of the lateral hypothalamus [8]. The most
likely mechanism is through descending inhibitory path-
ways that end in the dorsal horn of the spinal cord and
affect sensory centripetal neurotransmission.
However, serotonin agonists acting on 5-HT1a receptors
have also been shown to cause hyperalgesia in rats [9,10],
a finding observed by Fasmer et al. with lower doses of
buspirone as well [5]. In concordance to these reports, a
peripheral injection of 5-HT1a agonists produces dose-
dependent hyperalgesia, whereas 5-HT1a  antagonists
attenuate serotonin-induced hyperalgesia [11].
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5-HT1a  receptor antagonists, but not 5-HT1b  receptor
antagonists enhance the analgesic effects of tramadol
[12], thus providing evidence for an indirect effect of the
serotonergic system on descending pain control systems.
Similar effects were observed in a recent study which
found that 5-HT1a antagonism potentiates venlafaxine-
mediated analgesia, probably due to blockade of 5-HT1a
receptors in the raphe nucleus [13]. Furthermore, bus-
pirone inhibited morphine-associated analgesia in rats
[14].
These conflicting reports about the involvement of 5-HT1a
receptors in pain perception in animal studies have been
accompanied with only few studies in humans. Hoyer et
al. demonstrated that 5-HT1a receptors are abundant in
the human brain and spinal cord [15]. A recent study
showed a correlation of cold pressor pain and 5-HT1a
receptor binding in the human brain [16], but did not
address the question whether a reduction of 5-HT1a recep-
tor binding could affect pain perception. Only one study
analyzed the effects of buspirone on pain in humans:
Kishore-Kumar et al. [17] found that a single oral dose of
20 mg buspirone had no effect on postherpetic neuralgia
or painful neuropathy. No human studies on the effects of
a pharmacological manipulation of the serotonergic sys-
tem on acute sensory and pain perception have been pub-
lished so far.
The present study investigated the effect of buspirone on
thermal sensory and pain thresholds in human volun-
teers.
Methods
The investigation was designed as a prospective, rand-
omized, double-blind, double-dummy, placebo- and pos-
itive-controlled triple cross-over study. The study protocol
was approved by the institutional human studies commit-
tee of the University of Göttingen and complied with the
Declaration of Helsinki on Biomedical Research Involving
Human Subjects.
Twelve young, healthy, female volunteers aged 20–30
years were recruited. Exclusion criteria were: pre-existing
neurological disease, any acute or chronic drug or alcohol
use, diabetes mellitus, pregnancy, known allergy to the
tested substances, inability to communicate in the local
language and prior wounds or fractures on the tested
extremity. Concurrent drug use was ruled out by urine
testing on the trial days. Before commencing the study,
the subjects were introduced to the study protocol, gave
their written informed consent and had one trial thermo-
testing run prior to the actual measurements.
The study was conducted in three different sessions, seven
days apart. On each session, a peripheral venous cannula
was inserted and the participants received either 30 mg
buspirone p.o. (Bespar®, Bristol-Myers Squibb, Germany),
10 mg morphine i.v. (MSI-10®, Mundipharma, Germany)
in 100 ml saline infused over 15 minutes or placebo. Pla-
cebo tablets were prepared by the hospital pharmacy
department and were identical to the buspirone tablets.
Normal saline (100 ml) was infused over 15 minutes as
i.v. placebo. All participants received one tablet and one
infusion at each session. At the buspirone session (BUS)
they received a buspirone tablet and a dummy infusion of
saline, at the morphine session (MOR) they received a
dummy placebo tablet and a morphine infusion, and at
the placebo session (PLA) they received a placebo tablet
and intravenous saline.
Determination of sensory thresholds
Thermal thresholds were determined five minutes before
as well as 60 and 120 minutes after administration of the
tested substance, using the TSA-II Sensory analyzer®
(Medoc Ltd., Ramat Yishai, Israel) with a skin contact sur-
face area of the thermode of 9 cm2. This was attached to
the planar side of the forearm of the non-dominant arm
by means of an elastic Velcro® tape, taking care to ensure
that the entire surface of the thermode was in contact with
the skin.
The order in which the test drugs were administered to
each participant was randomized in a block design prior
to the study. The same investigator, who was blinded to
the group allocation, performed all tests.
The basal skin adaptation temperature of the thermode
was set to 32°C. After an accommodation period of five
minutes at this temperature, the tests were performed
using the method of limits, with temperature change of
1°C sec-1 for heat and cold detection and 4°C sec-1 for
heat pain and cold pain threshold testing and rapid return
to the basal temperature. The more rapid temperature
change used to determine pain thresholds was chosen to
avoid sensitization of the skin due to the thermal stimuli.
All tests were performed in the same quiet room with a
constant room temperature of 21°C and always started at
9 a.m. No visual or auditory cues were given to indicate
stimulus onset. The sensory qualities were always tested in
the same order: cold detection threshold (CDT), cold pain
detection threshold (CPDT), heat detection threshold
(HDT) and heat pain detection threshold (HPDT). Four
measurements were performed for each threshold and the
results were averaged. There was a pause of at least ten sec-
onds between each measurement.
Heart rate, blood pressure and Ramsay sedation score
(RSS) [18] were assessed before each threshold determi-
nation. With the latter, patients are classified on a scale
from 1 (anxious and restless) to 6 (no response to stimu-
lus).BMC Clinical Pharmacology 2009, 9:12 http://www.biomedcentral.com/1472-6904/9/12
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Data analysis
Data are presented as means and standard deviation
(unless otherwise stated). Data analysis was carried out
with the Statistica program Version 7.1 (StatSoft, Tulsa,
OK, USA) in cooperation with our department of biomed-
ical statistics. Thermal sensory and pain detection thresh-
old data were tested for normal distribution with the
Kolmogorov-Smirnov test and then analyzed with multi-
ple t-tests for paired data with Tukey-Krame correction
factor for multiple comparisons. P-values lower than 0.05
were considered significant.
Results
The mean age of the participants was 26.5 ± 2.4 years.
None of the participants were pregnant, suffered from
neurological diseases or were taking any acute or chronic
medication. None of the participants dropped out of the
study and all drug-screening tests were negative.
All participants were cooperative and tranquil (Ramsay
score 2) at the start of each session. Blood pressure and
heart rate were not affected by either of the tested sub-
stances at any tested time point (Figure 1).
Buspirone caused sedation in half of the patients at 60
minutes (Figure 2), but this has largely resolved at 120
minutes. No other side effects were observed or reported.
Morphine resulted in a higher incidence and a higher
degree of sedation at sixty minutes after drug administra-
tion. Four participants complained of dizziness and four
of nausea following the infusion of morphine.
Morphine significantly increased the heat pain detection
threshold at the two time points, both compared to base-
line as well as placebo (Figure 3). The changes of the
thresholds for cold detection and cold pain detection fol-
lowing morphine administration were formally non-sig-
nificant according to our criteria (p = 0.08 and p = 0.07,
respectively, compared to placebo).
Buspirone did not cause a significant change in any of the
tested sensory thresholds at either time point after its
administration, nor was there any difference compared to
the placebo at respective times.
Discussion
This is the first published study of the effects of a 5-HT1a
partial agonist on acute thermal sensation and pain per-
ception in human subjects.
A gender homogenous group was deliberately recruited
for this study to avoid the documented influence of gen-
Hemodynamic parameters Figure 1
Hemodynamic parameters. Hemodynamic parameters 60 and 120 minutes following buspirone and morphine administra-
tion: The values are expressed as change in the blood pressure or heart rate from the pre-treatment value. a) Systolic blood 
pressure change, b) Heart rate change. Blood pressure and heart rate changes following the two drugs were not significantly 
different than with placebo (p < 0.05). BP0', BP60', BP120' = systolic blood pressure at the time of drug administration (0) and 60 
and 120 minutes after drug administration. HR0', HR60', HR120' = heart rate at the time of drug administration (0) and 60 and 
120 minutes after drug administration.BMC Clinical Pharmacology 2009, 9:12 http://www.biomedcentral.com/1472-6904/9/12
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der on pain perception and pain reporting, which could
have affected data dispersion and complicated data anal-
ysis [19,20]. We chose female participants, since the inves-
tigator performing the threshold testing was a woman and
this could have influenced the response of male partici-
pants [21,22].
Morphine induced a significant increase in the heat pain
threshold, indicating that the study design was valid and
capable of detecting an analgesic effect on heat pain. The
changes in the other three sensory thresholds after mor-
phine administration were not statistically significant
compared to placebo, however, the calculated p-values of
0.08 and 0.07 for CDT and CPDT, respectively, indicate
that this may have been due to insufficient power of the
study group size. We found no significant effect of bus-
pirone in the highest recommended clinical dose on the
tested thermal thresholds. The reason for this could be
due to the pharmacodynamics of buspirone itself or to the
details of the study design.
Mico et al. [23] have linked the effects of serotonin on
nociception to its action on 5-HT1A  somatodendritic
autoreceptors in the raphe nucleus that control descend-
ing inhibitory pathways involved in the control of rostral
nociceptive transmission. As described above, buspirone
and other 5-HT1A receptor agonists can alter the response
to pain in experimental animals, but the effects are com-
plicated and depend to some extent on the study design.
Murphy et al. [10] found that stimulation of 5-HT1A recep-
tors raised the threshold to thermal pain, but decreased it
with regard to mechanical pain. The 5-HT1A  agonist
F13640 was shown to induce both hyperalgesia and anal-
gesia depending on the time after administration and thus
possibly depending on the drugs' plasma concentrations
[24] with higher concentrations associated with hyperal-
gesia.
Buspirone was without effect on tail-flick latency in the
hot-plate test in rats but significantly attenuated the anal-
gesic effects of morphine [14]. The 5-HT1A agonist 8-OH-
DPAT similarly attenuated the analgesic effect of acetami-
nophen in the hot-plate test in mice [25].
The affinity of buspirone is highest for 5-HT1A receptors
but it is not entirely specific and also acts on other recep-
tors including an antagonistic effect on DA2 dopamine
receptors. This partial agonistic and somewhat non-spe-
cific action on 5-HT1A receptors could possibly explain the
spectrum of its actions.
Factors unrelated to the relevance of 5-HT1A receptors in
the modulation of pain perception may also have contrib-
uted to the lack of effect in the present study. The temper-
ature change rate of 4°C sec-1 used to determine pain
thresholds was chosen in order to reduce sensitization of
the skin due to the repeated thermal stimuli, but this may
have been too rapid to detect only small alterations of the
threshold.
Buspirone has a high hepatic extraction ratio and high
first-pass metabolism after oral administration resulting
in low bioavailability [26]. While the plasma and CNS
concentrations present one hour after administering the
maximal recommended dose of 30 mg were adequate to
cause sedation, they might not have been sufficient for an
analgesic effect. However, should buspirone have analge-
sic effects at a higher dose, the significant sedative side-
effects would probably limit its clinical usefulness. Studies
of acute pain in humans using more specific 5-HT1A recep-
tor agonists will be required to define their potential use
in analgesia or pain modulation.
Conclusion
This first human study on the effect of a 5-HT1A receptor
agonist buspirone on acute thermal sensory and pain per-
ception demonstrated that buspirone in a clinically rele-
vant dose has no effect on thermal sensory and pain
perception. It does not rule out a possibility that more
specific 5-HT1A receptor agonists might have analgesic
effects.
Sedation scores Figure 2
Sedation scores. Ramsay sedation scores for the subjects 
before and 60 and 120 minutes following the drug adminis-
tration. The initial score always 2 (cooperative and tranquil) 
in all participants. * = statistical significance of the Ramsay 
scores compared to pretreatment score (p < 0.05). ** = sta-
tistical significance of the Ramsay scores compared to pla-
cebo at the same time point (p < 0.05).BMC Clinical Pharmacology 2009, 9:12 http://www.biomedcentral.com/1472-6904/9/12
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